Secarna Pharmaceuticals announced today that results from preclinical studies targeting ROR(gamma)t with an innovative antisense oligonucleotide approach will be presented at the 5th European Congress of Immunology (ECI).
Munich/Martinsried, Germany, August 30, 2018 – Secarna Pharmaceuticals (“Secarna”), a new breed biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets in a number of organ systems, announced today that results from preclinical studies targeting ROR(gamma)t with an innovative antisense oligonucleotide approach will be presented at the 5th European Congress of Immunology (ECI). The meeting will be held from September 2 to 5, 2018 in Amsterdam, The Netherlands.
The poster presentation titled “Targeting RORgt with antisense oligonucleotides impairs Th17 development in vitro” will be given by Dr. Anne Sadewasser.
| Session Name: | P.C2.11 – Immune signaling and therapy in autoimmunity – Part 11 |
| Presentation Date and Time: | Wednesday, September 5, 2018, 10:15-11:45 AM CEST |
| Venue: | RAI Exhibition and Convention Centre, Hall 10 (Track C), |
Secarna’s proprietary LNAplus™ ASO specifically binds and degradates RORC2 mRNA, which encodes the RORgt protein. RORgt is the master transcription factor of Th17 cells and constitutes an attractive therapeutic target for many Th17-mediated diseases, for example inflammatory bowel disease or psoriasis.
Jonas Renz, Managing Director and co-founder of Secarna Pharmaceuticals, commented: “RORgt is a well-know, validated, but also elusive target. Small molecule approaches have not advanced into late stage clinical development. We have overcome the limitations of previous approaches and developed the first true RORgt-specific inhibitor utilizing our proprietary third generation LNAplus™ platform. Our findings show that RORgt-specific ASOs provide a promising approach to treat Th17-driven diseases. We are thrilled that ECI offers us the platform to discuss our data with academia and interested industry partners.”
The abstract can be accessed online at https://bit.ly/2MLVAgJ
About Secarna Pharmaceuticals GmbH & Co. KG
Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immunooncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets. www.secarna.com
Contact
Jonas Renz
Managing Director and Co-Founder
Secarna Pharmaceuticals GmbH & Co. KG
Am Klopferspitz 19
82152 Planegg/Martinsried
Tel.: +49 (0)89 215 46 375
- End of Press Release -
Should you have any questions or would like ot receive further information, please do not hesitate to contact us.
Best regards
For media enquiries:
Anne Hennecke
MC Services AG
anne.hennecke@mc-services.eu
Tel.: +49 (0)211.52 92 52 22
MC Services AG
Handelsregister/Commercial Register: Amtsgericht Augsburg HRB 2117
Vorstand/Management Board: Raimund Gabriel, Anne Hennecke
Aufsichtsrat/Supervisory Board: Johannes Gabriel (Vorsitzender/Chairman)
